Search PubMed⌕ Search

Biomedical subjects

C Haslett

Publications and source records attributed to C Haslett.

131 records · Page 8Linked to original sources
PubMed1983

Rheumatic heart disease and thyroid status.

A retrospective analysis of 76 patients with rheumatic heart disease revealed nine with thyrotoxicosis, three with hypothyroidism and seven with normal thyroid function and circulating thyroid antibodies. This suggests that there may be an association between rheumatic heart disease and thyroid dysfunction. The findings emphasize the need to formally exclude hyperthyroidism in patients with atrial fibrillation whatever the apparent cause. They also imply a possible autoimmune factor in the pathogenesis of rheumatic heart disease and suggest that patients with rheumatic heart disease may develop clinical or sub-clinical thyroid disease.

Adult↗
PubMed1983

A double-blind evaluation of evening primrose oil as an antiobesity agent.

Evening Primrose Oil (EPO) is a naturally occurring rich source of essential fatty acids, especially linoleic and gamma-linolenic acid. It has been suggested that it has antiobesity properties. This double-blind 12-week study was undertaken in 100 women with substantial obesity: 40 with refractory obesity, and 60 at time of initial referral to a hospital clinic. Seventy-four subjects completed the study. Those treated with EPO were comparable in age and degree of obesity with the placebo-treated group. There was no significant difference in the weight loss achieved by those taking EPO compared with placebo, either in the subjects with refractory obesity or in those treated at time of initial referral. It would appear that any antiobesity property possessed by EPO is clinically insignificant.

Adolescent↗
PubMed1981

Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis.

In a double-blind placebo-controlled trial in 24 patients fulfilling the MRC criteria for chronic bronchitis, oral salbutamol 4 mg and slow-release aminophylline (Phyllocontin) 450 mg produced similar and significant (p less than 0.05) mean increases in forced expiratory volume in one second (FEV1). A significantly greater increase in mean FEV1 and forced vital capacity (FVC) was seen when both drugs were given although there was no statistical evidence of synergistic interaction. Salbutamol significantly increased the mean distance walked in 12 minutes (12MD) (p less than 0.02) by 56 metres and a similar increase of 54 metres (p less than 0.001) was seen after Phyllocontin. With both drugs in combination mean 12MD increased by 51 metres (p less than 0.02 cf placebo), a change not significantly different from that observed with either drug alone. Oral salbutamol and Phyllocontin improve exercise tolerance in chronic bronchitis. The significantly greater changes in FEV1 and FVC resulting from simultaneous administration of the two drugs are not associated with further improvement in exercise tolerance.

Adult↗